purpos
system
juvenil
idiopath
arthriti
chronic
pediatr
diseas
initi
clinic
present
mimic
pediatr
inflammatori
condit
often
lead
signific
delay
diagnosi
appropri
therapi
sjia
biomark
develop
unmet
diagnosticprognost
need
prevent
diseas
complic
experiment
design
profil
urin
peptidom
analyz
set
urin
sampl
patient
sjia
kawasaki
diseas
kd
febril
ill
fi
healthi
control
set
plasma
sampl
sjia
flare
quiescent
patient
profil
use
custom
antibodi
array
protein
known
involv
inflammatori
protein
catabol
process
result
identifi
biomark
panel
could
effect
discrimin
sjia
patient
activ
quiescent
remiss
diseas
state
patient
activ
sjia
confound
condit
includ
kd
fi
target
sequenc
peptid
reveal
fall
sever
tight
cluster
seven
differ
protein
suggest
diseasespecif
proteolyt
activ
antibodi
array
plasma
profil
identifi
sjia
plasma
flare
signatur
consist
tissu
inhibitor
interleukin
il
regul
upon
activ
normal
cell
express
secret
rant
pselectin
lselectin
urin
peptidom
plasma
protein
analys
potenti
improv
sjia
care
suggest
sjia
urin
peptid
clinic
relev
sensit
specif
diagnost
biomark
system
onset
juvenil
idiopath
arthriti
sjia
would
allow
differenti
febril
ill
kawasaki
diseas
kd
acut
infect
febril
ill
fi
facilit
prompt
initi
appropri
treatment
diseas
onset
earli
treatment
may
reduc
risk
longterm
complic
subsequ
disabl
addit
biomark
distinguish
intercurr
sjia
flare
infect
patient
known
sjia
would
clinic
use
would
marker
predict
impend
diseas
flare
respond
statu
particular
therapi
provid
earli
indic
treatment
respons
final
biomark
may
provid
clue
unansw
question
concern
sjia
pathogenesi
compar
analysi
sjia
kd
fi
urin
peptidom
identifi
small
subset
urin
peptidom
effect
discrimin
sjia
patient
activ
quiescent
remiss
diseas
state
also
discrimin
patient
activ
sjia
confound
condit
includ
kd
fi
urin
peptid
diagnost
prognost
biomark
could
clinic
use
especi
serial
sampl
pediatr
sjia
patient
target
sequenc
reveal
peptid
marker
fall
sever
tight
cluster
indic
sjiaspecif
proteolyt
event
plasma
catalog
analysi
normal
plasma
peptidom
show
least
nest
peptid
marker
origin
circul
custom
antibodi
array
use
compar
plasma
abund
protein
known
involv
inflammatori
protein
catabol
process
reveal
sjia
flare
signatur
taken
altogeth
urin
peptidom
plasma
protein
peptid
analys
suggest
testabl
model
sjia
urin
peptid
biomark
may
outcom
inflammationdriven
effect
catabol
pathway
oper
multipl
site
electron
supplementari
materi
onlin
version
articl
contain
supplementari
materi
avail
author
user
biomark
may
outcom
inflammationdriven
effect
catabol
pathway
oper
multipl
site
system
onset
juvenil
idiopath
arthriti
chronic
inflammatori
diseas
childhood
character
combin
system
featur
fever
rash
seros
eg
pericard
pleuriti
arthriti
current
diagnosi
sjia
base
sole
clinic
find
requir
arthriti
daili
fever
least
week
least
one
follow
evanesc
erythemat
rash
gener
lymph
node
enlarg
hepatomegali
andor
splenomegali
seros
make
earli
diagnosi
sjia
challeng
clinic
manifest
similar
diseas
includ
malign
infect
kawasaki
diseas
kd
autoimmun
inflammatori
disord
longterm
diseas
outcom
sjia
variabl
patient
experi
singl
episod
resolv
howev
half
experi
either
polycycl
nonremit
diseas
sensit
specif
diagnost
biomark
sjia
would
allow
differenti
febril
ill
kd
acut
infect
febril
ill
fi
facilit
prompt
initi
appropri
treatment
diseas
onset
earli
treatment
may
reduc
risk
longterm
complic
subsequ
disabl
addit
biomark
distinguish
intercurr
sjia
flare
infect
patient
known
sjia
would
clinic
use
would
marker
predict
impend
diseas
flare
respond
statu
particular
therapi
provid
earli
indic
treatment
respons
final
biomark
may
provid
clue
unansw
question
concern
sjia
pathogenesi
sever
previou
biomark
discoveri
effort
sjia
initi
studi
includ
attempt
identifi
earli
clinic
variabl
predict
longterm
outcom
joint
damag
function
disabl
year
diseas
onset
studi
serum
found
elev
cytokin
chemokin
acutephas
reactant
activ
sjia
recent
transcript
profil
peripher
blood
mononuclear
cell
sjia
subject
activ
diseas
reveal
signatur
activ
sjia
normal
associ
clinic
respons
treatment
singl
seldibas
analysi
plasma
identifi
serum
amyloid
plasma
biomark
diseas
activ
howev
effort
fall
short
robust
diagnost
prognost
biomark
practic
clinic
util
sought
explor
urin
sourc
biomark
marker
would
permit
frequent
test
would
use
especi
children
chronic
pediatr
diseas
polycycl
cours
normal
adult
human
excret
mg
protein
mg
peptid
per
day
urin
urin
proteom
analysi
identifi
protein
includ
larg
proport
membran
protein
urin
peptidom
analysi
reveal
differ
peptid
indepth
mass
spectra
ms
msm
analysi
led
identif
differ
urin
peptid
sequenc
uniqu
protein
precursor
normal
human
urin
recent
review
indic
analysi
urinari
proteomepeptidom
highli
inform
urogenit
system
diseas
use
diseas
classif
natur
process
urin
peptid
certain
advantag
protein
biomark
roughli
equal
mass
protein
peptid
urin
translat
least
tenfold
greater
molar
abund
peptid
urin
proteom
contain
number
abund
protein
obscur
lower
abund
protein
like
biomark
problem
complic
analysi
peptid
urin
onedimension
hplc
separ
suffici
analysi
greater
urin
distinct
peptid
among
emerg
quantit
proteom
technolog
isobar
tag
rel
absolut
quantif
itraq
allow
concurr
protein
sequenc
identif
rel
quantif
peptid
known
protein
sequenc
eight
differ
biolog
sampl
singl
experi
howev
due
limit
throughput
current
cost
itraq
feasibl
simultan
comparison
larg
number
diseas
subject
need
achiev
discoveri
differenti
featur
suffici
statist
power
altern
labelfre
liquid
chromatographymass
spectrometri
lcm
base
approach
appli
quantit
biomark
discoveri
method
labelfre
lcm
approach
compar
quantifi
peptid
precis
accuraci
compar
base
isotop
label
although
lcesi
mass
spectrometri
typic
use
labelfre
quantit
proteom
matrixassist
laser
desorptionionizationtimeofflight
malditof
mass
spectrometri
increasingli
use
demonstr
low
averag
coeffici
variat
peptid
signal
across
entir
intens
rang
technic
replic
use
labelfre
lcmalditof
profil
approach
previous
discov
candid
urin
peptid
biomark
renal
transplant
reject
subsequ
urin
peptid
biomark
valid
multipl
reaction
monitor
mrm
show
signific
correl
urin
peptid
measur
obtain
labelfre
malditof
mrm
use
stabl
isotopelabel
synthet
marker
analogu
deriv
absolut
quantif
labelfre
lcmalditof
approach
involv
comparison
urin
peptidom
differ
sampl
thu
multipl
lcm
spectra
howev
compar
multipl
lcm
spectra
labelfre
analysi
comput
intens
demand
robust
detect
lcm
peak
align
lcm
peak
determin
common
peak
indic
across
assay
sampl
output
data
process
essenti
p
x
n
tabl
index
p
peptid
quantifi
across
n
studi
sampl
tabl
reduc
lcm
spectra
sampl
subject
downstream
statist
learn
includ
transform
normal
unsupervisedsupervis
analys
suit
experiment
design
mine
differenti
subset
p
peptid
subject
msm
protein
sequenc
identif
futur
quantit
prospect
mrm
antibodybas
valid
identifi
natur
occur
urin
peptid
specif
activ
system
sjia
compar
sourc
fever
hypothes
sjia
flare
associ
increas
level
circul
mediat
inflamm
activ
catabol
pathway
lead
gener
novel
peptid
biomark
found
urin
test
hypothesi
global
lcm
analysi
urin
plasma
peptid
well
target
analysi
plasma
protein
use
antibodi
array
follow
reagent
use
proteom
sampl
analysi
nanopur
milliq
qualiti
water
megohm
cm
better
amicon
ultra
centrifug
filtrat
tube
obtain
millipor
bedford
usa
ammonium
bicarbon
ammonium
format
formic
acid
obtain
fluka
st
loui
mo
usa
trishcl
urea
thiourea
dtt
iodoacetamid
calcium
chlorid
tfa
obtain
sigmaaldrich
st
loui
mo
usa
hplcgrade
methanol
meoh
hplcgrade
acn
purchas
fisher
scientif
fair
lawn
nj
usa
obtain
aldrich
chemic
milwauke
wi
usa
sequenc
grademodifi
trypsin
purchas
promega
madison
wi
usa
sodium
tetrabor
glycin
picrylsuofon
acid
obtain
sigmaaldrich
st
loui
mo
usa
inform
consent
obtain
parent
patient
assent
patient
year
age
studi
approv
human
subject
protect
program
ucsd
ucsf
stanford
univers
urin
sampl
obtain
two
new
onset
sjia
diseas
nd
activ
system
diseas
plu
arthriti
saf
nine
sjiawith
activ
arthriti
af
quiescent
sjia
medic
qom
nine
sjia
remiss
medic
rd
ten
healthi
control
hc
stanford
univers
medic
center
ucsf
addit
urin
sampl
obtain
kd
agesimilar
fi
control
patient
evalu
fever
radi
children
hospit
san
diego
kd
patient
fever
five
princip
clinic
criteria
kd
rash
conjunctiv
inject
cervic
lymphadenopathi
chang
oral
mucosa
chang
extrem
three
criteria
plu
coronari
arteri
abnorm
document
echocardiographi
fi
control
patient
nasoor
oropharyng
stool
viral
cultur
urin
sampl
patient
demograph
describ
tabl
sjia
kd
fi
plasma
sampl
includ
sjia
flare
f
sjia
q
train
analysi
sjia
f
q
bootstrap
test
analysi
instead
silico
bootstrap
simul
sampl
belong
differ
visit
patient
even
sampl
assay
ie
bootstrap
experiment
test
bootstrap
test
total
sjia
sampl
analyz
antibodi
array
sampl
patient
time
sjia
flare
sampl
eight
patient
time
sjia
quiescenc
plasma
sampl
patient
demograph
describ
tabl
urin
sampl
ml
collect
steril
tube
held
h
centrifug
min
room
temperatur
freez
supernat
urin
process
prepar
peptid
extract
fraction
previous
describ
urinari
sampl
process
centrifug
filtrat
min
amicon
ultra
centrifug
filtrat
devic
kda
cutoff
millipor
bedford
preequilibr
ml
milliq
water
filtrat
urin
peptidom
contain
low
mw
natur
occur
peptid
process
water
oasi
hlb
extract
cartridg
water
corpor
milford
extract
ethyl
acet
result
urin
peptid
sampl
quantifi
acid
tnb
assay
previous
describ
three
nanomol
peptid
inject
cm
reversephas
column
michrom
elut
gradient
acetonitril
min
use
michrom
hplc
twentysecond
fraction
collect
onto
maldi
target
probot
fraction
collector
lc
pack
total
fraction
collect
analyz
malditoftof
appli
biosystem
ms
mode
one
microlit
matrix
solut
contain
mgml
acid
agil
technolog
palo
alto
ca
usa
glufibrinopeptid
sigmaaldrich
st
loui
mo
usa
automat
deposit
probot
spot
plasma
peptidom
prepar
protocol
adapt
urin
peptidom
analysi
plasma
sampl
centrifug
min
amicon
ultra
centrifug
filtrat
devic
kda
cutoff
millipor
bedford
preequilibr
ml
milliq
water
retent
plasma
proteom
wash
twice
brought
final
volum
mm
trishcl
ph
quantit
bca
protein
assay
pierc
rockford
il
filtrat
plasma
peptidom
contain
low
mw
natur
occur
peptid
process
water
oasi
hlb
extract
cartridg
water
corpor
milford
extract
ethyl
acet
result
plasma
peptid
sampl
quantifi
tnb
assay
previous
describ
three
nanomol
peptid
fraction
twodimension
chromatographya
scx
column
first
rp
column
second
dimens
subject
extens
msm
sequenc
identif
involv
thermo
finnigan
ltqfticr
spectromet
abi
oracl
databas
ms
spectra
export
raw
data
point
via
abi
explor
softwar
version
subsequ
data
analys
mz
rang
peak
densiti
maximum
peak
per
da
minim
sn
ratio
minim
area
minim
intens
maximum
peak
per
spot
previous
develop
informat
platform
contain
integr
set
algorithm
statist
method
comput
applic
allow
ms
data
process
statist
analysi
lcmsbase
urin
peptid
profil
ms
peak
locat
raw
spectra
maldi
data
algorithm
identifi
site
masstocharg
ratio
mz
valu
whose
intens
higher
estim
averag
background
surround
site
peak
correspond
mz
valu
align
peak
set
spectra
assay
sampl
appli
linkag
hierarch
cluster
collect
peak
individu
spectra
cluster
comput
linux
cluster
two
dimension
use
distanc
along
mz
axi
hplc
fraction
time
concept
tight
cluster
repres
biolog
peak
slightli
shift
differ
spectra
extract
centroid
mean
posit
cluster
repres
consensu
posit
peak
index
bin
across
spectra
normal
malditof
signal
intens
peptid
featur
perform
two
step
within
lc
fraction
maldi
plate
spot
peptid
peak
signal
intens
normal
extern
spike
refer
peptid
glufibrinopeptid
maldi
plate
spot
cluster
peptid
uniqu
z
lc
fraction
time
normal
total
signal
intens
cluster
peptid
within
sampl
urin
peptidom
analysi
use
approach
ion
map
wherebi
biomark
candid
ms
peak
select
basi
discrimin
analysi
target
msm
sequenc
analysi
obtain
protein
identif
extens
malditoftof
ltq
orbitrap
msm
analys
coupl
databas
search
perform
sequenc
identifi
peptid
biomark
ident
subset
peptid
detect
determin
search
msm
spectra
swissprot
databas
june
restrict
human
entri
sequenc
use
mascot
version
search
engin
search
restrict
ppm
parent
fragment
ion
respect
enzym
restrict
select
sinc
focus
natur
occur
peptid
hit
consid
signific
statist
signific
threshold
return
mascot
select
msm
spectra
also
search
sequest
intern
protein
index
human
databas
version
restrict
human
entri
sequenc
mmass
open
sourc
mass
spectrometri
tool
http
mmassbiographicscz
use
manual
review
protein
identif
msm
ion
pattern
analysi
addit
valid
custom
antibodi
array
consist
pair
captur
detect
antibodi
protein
util
ifng
antibodi
array
fabric
process
data
extract
analysi
perform
previou
describ
patient
demograph
data
analyz
use
epidemiolog
calcul
r
epicalc
packag
version
bin
lcmaldi
ms
peak
data
obtain
urin
peptidom
sampl
analyz
discoveri
discrimin
biomark
use
algorithm
nearest
shrunken
centroid
nsc
biomark
featur
select
tenfold
crossvalid
analys
gaussian
linear
discrimin
analysi
lda
classif
analys
control
number
fals
signific
featur
found
nsc
mine
permut
data
set
time
calcul
gfdr
quantifi
differ
class
identifi
peptid
biomark
student
test
mannwhitney
u
test
use
hypothesi
test
local
fals
discoveri
rate
fdr
tool
use
correct
multipl
hypothesi
test
order
test
whether
select
discrimin
featur
could
serv
diagnost
biomark
panel
logist
regress
model
use
find
linear
combin
biomark
minim
total
classif
error
order
avoid
bia
data
set
util
bootstrap
techniqu
bootstrap
time
evalu
impact
data
construct
overal
classif
perform
biomark
panel
bootstrap
set
use
ldaderiv
predict
score
sampl
construct
receiv
oper
characterist
roc
curv
summar
result
vertic
averag
roc
curv
plot
box
whisker
use
describ
vertic
spread
around
averag
collect
intraday
urin
sampl
pediatr
sjia
patient
two
site
stanford
ucsf
tabl
includ
patient
nd
saf
af
sjia
quiescenc
inact
diseas
medic
qom
sjia
remiss
inact
diseas
medic
rd
comparison
sampl
subject
kd
acut
fi
tabl
collect
ucsd
healthi
agematch
control
hc
collect
stanford
collect
also
collect
plasma
sampl
pediatr
sjia
patient
tabl
includ
patient
saf
avail
plasma
sampl
multipl
visit
consid
experiment
bootstrap
sampl
sjia
patient
differ
diseas
state
also
collect
confirmatori
analys
use
bootstrap
thirteen
patient
provid
urin
plasma
sampl
expect
base
known
differ
demograph
differ
age
gender
distribut
sjia
kd
fi
urin
subject
except
nd
patient
median
age
year
rang
year
sjia
patient
saf
median
age
year
rang
year
af
median
age
year
rang
year
qom
median
age
year
rang
year
rd
median
age
year
rang
year
older
kd
median
age
year
rang
year
fi
median
age
year
rang
year
patient
except
nd
patient
male
fewer
male
sjia
patient
saf
male
af
male
qom
male
rd
male
kd
male
fi
male
patient
expect
activ
tabl
mass
spectrometrybas
urin
peptidom
analys
suffer
two
major
sourc
varianc
analyt
issu
includ
mass
spectrometr
ion
suppress
biolog
issu
includ
dilut
urin
differ
hydrat
state
urin
donor
standard
amount
urin
peptid
compar
analysi
quantifi
extract
urin
peptidom
tnb
assay
nmol
peptid
subject
downstream
lcmalditof
profil
analysi
initi
step
biomark
discoveri
effort
collect
urin
peptid
spectra
lcmalditof
profil
urin
sampl
ms
spectrum
hplc
fraction
analyz
massconductor
softwar
ling
unpublish
extract
peak
raw
maldi
spectra
enabl
common
peak
align
gener
consensu
repres
peak
across
spectra
via
twodimension
hierarch
cluster
mass
charg
hplc
fraction
normal
peak
signal
measur
discov
sjia
system
flare
signatur
urin
spectra
subject
system
activ
diseas
sjia
nd
saf
patient
compar
simultan
nonsystem
group
sjia
af
qom
patient
system
inflamm
group
kd
fi
data
mine
process
includ
select
discrimin
urin
bootstrap
differ
silico
bootstrap
resampl
simul
sampl
belong
differ
visit
patient
even
sampl
assay
ie
bootstrap
experiment
peptid
supervis
classif
bootstrap
roc
analysi
outlin
fig
classifi
discoveri
featur
select
nsc
algorithm
perform
use
featur
data
set
nsc
algorithm
iter
shrink
standard
class
mean
abund
peptid
eventu
urin
peptid
rank
differ
shrunken
class
mean
tenfold
intern
crossvalid
analysi
lda
led
discoveri
biomark
panel
biomark
effect
differenti
sjia
flare
nd
saf
contrast
group
af
qom
rd
kd
fi
sampl
extens
malditof
tof
ltq
orbitrap
msm
analysi
coupl
databas
search
perform
identifi
peptid
biomark
shown
tabl
biomark
found
degrad
product
eight
differ
protein
antitrypsin
two
peptid
overlap
sequenc
collagen
type
alpha
five
peptid
three
overlap
sequenc
collagen
type
alpha
one
peptid
collagen
type
iii
alpha
one
peptid
collagen
type
ix
alpha
one
peptid
fibrinogen
alpha
fga
two
peptid
overlap
sequenc
fibrinogen
beta
fgb
two
peptid
overlap
sequenc
uromodulin
umod
three
peptid
overlap
sequenc
sequenc
align
peptid
biomark
reveal
tight
sequenc
cluster
fga
fgb
umodderiv
biomark
mannwhitney
u
test
tabl
perform
evalu
signific
discrimin
bootstrap
differ
silico
bootstrap
resampl
simul
sampl
belong
differ
visit
patient
even
sampl
assay
ie
bootstrap
experiment
tabl
fig
evalu
biomark
panel
classifi
sjia
versu
system
inflamm
kawasaki
diseas
acut
febril
ill
logist
regress
model
use
find
panelbas
algorithm
minim
total
classif
error
discrimin
sjia
system
diseas
inflamm
due
kdfi
maximum
estim
probabl
wrongli
classifi
sampl
label
arrow
b
modifi
conting
tabl
show
percentag
classif
agre
clinic
diagnosi
c
discrimin
analysisderiv
predict
score
sampl
use
construct
receiv
oper
characterist
roc
curv
test
data
set
gener
bootstrap
sjia
system
flare
kd
fi
data
use
deriv
estim
standard
error
confid
interv
roc
analysi
plot
roc
curv
vertic
averag
bootstrap
run
box
whisker
plot
show
vertic
spread
around
averag
distribut
standard
roc
auc
valu
fals
discov
panel
upon
classlabel
permut
data
set
cohort
sjia
f
kdfi
urin
peptidom
examin
fals
discov
biomark
panel
roc
auc
valu
number
fals
discov
sames
panel
roc
auc
valu
greater
origin
urin
biomark
panel
repres
red
vertic
line
divid
total
number
fals
discov
biomark
panel
led
estim
fals
discoveri
rate
fdr
seventeenurinepeptid
biomark
panel
effect
discrimin
sjia
flare
kd
fi
order
test
whether
biomark
could
collect
serv
diagnost
biomark
panel
logist
regress
model
use
find
linear
combin
biomark
minim
total
classif
error
discrimin
sjia
system
nd
saf
patient
kd
fi
patient
figur
plot
linear
discrimin
probabl
peptid
biomark
panel
sampl
good
separ
highest
next
highest
probabl
classif
seventeen
sjia
flare
nonsjia
kd
fi
patient
correctli
classifi
maximum
estim
probabl
wrongli
classifi
sampl
label
arrow
modifi
conting
tabl
fig
evalu
perform
peptid
panel
separ
sjia
flare
kd
fi
use
discrimin
analysisderiv
predict
score
sampl
construct
roc
curv
addit
util
bootstrap
resampl
techniqu
construct
multipletest
data
set
evalu
classif
perform
biomark
panel
figur
summar
bootstrap
run
sjia
system
flare
kd
fi
sampl
deriv
estim
standard
error
confid
interv
roc
analysi
plot
roc
fig
curv
vertic
averag
bootstrap
run
box
whisker
plot
vertic
spread
around
averag
roc
analysi
yield
averag
area
curv
auc
valu
indic
high
perform
next
sought
determin
whether
panel
biomark
could
serv
flare
signatur
discrimin
sjia
flare
sampl
sampl
patient
qom
rd
logist
regress
model
use
find
linear
combin
biomark
minim
total
classif
error
classifi
patient
sjia
system
flare
qom
rd
figur
plot
linear
discrimin
probabl
peptid
biomark
panel
sampl
good
separ
highest
next
highest
probabl
classif
eighteen
sjia
flare
sjia
quiescent
remiss
patient
correctli
classifi
maximum
estim
probabl
wrongli
classifi
sampl
label
arrow
modifi
conting
tabl
fig
show
percentag
classif
agre
clinic
diagnosi
overal
biomark
panel
classifi
sjia
flare
sampl
posit
agreement
clinic
diagnosi
quiescent
remiss
sampl
agreement
clinic
diagnosi
figur
summar
bootstrap
run
sjia
system
flare
quiescent
remiss
sampl
deriv
estim
standard
error
confid
interv
roc
analysi
plot
roc
fig
curv
vertic
averag
bootstrap
run
box
whisker
plot
vertic
spread
around
averag
roc
analysi
yield
auc
valu
roc
analys
biomark
panel
discrimin
sjia
f
versu
qomrd
sjia
f
versu
kdfi
bootstrap
resampl
techniqu
use
avoid
bia
due
presenc
outlier
assay
sampl
case
shown
roc
plot
roc
analys
fig
yield
signific
auc
indic
roc
curv
affect
significantli
bootstrap
process
demonstr
robust
biomark
panel
discrimin
analys
observ
high
throughput
analys
eg
microarray
express
profil
number
profil
featur
greatli
exce
assay
sampl
concurr
analysi
malditof
spectral
peak
evalu
null
hypothes
differenti
urin
peptid
biomark
lead
multipletest
problem
address
multiplehypothesi
test
problem
estim
fdr
concurr
statist
test
peptid
panel
size
biomark
panel
multipl
permut
random
train
data
set
construct
class
label
train
sampl
either
cohort
sjia
f
qomrd
cohort
sjia
f
kdfi
permut
time
time
everi
sampl
would
randomli
assign
new
class
label
sjia
f
qomrd
f
qomrd
discrimin
sjia
f
kdfi
sjia
f
kdfi
discrimin
simul
train
set
nsc
algorithm
appli
rank
malditof
spectral
peak
featur
base
upon
abil
discrimin
binari
class
sjia
f
versu
qomrd
sjia
f
versu
kd
fi
respect
nscselect
top
featur
design
panel
lda
analysi
roc
analysi
subsequ
use
calcul
auc
fals
discov
panel
auc
valu
fals
discov
panel
standard
densiti
distribut
plot
fig
fdr
calcul
number
auc
valu
greater
panel
divid
total
number
auc
valu
fals
discov
panel
shown
fig
fdr
urin
peptid
biomark
panel
estim
sjia
f
versu
qomrd
discrimin
sjia
f
versu
kd
fi
discrimin
respect
result
support
notion
discoveri
peptid
biomark
panel
fig
evalu
biomark
panel
classifi
activ
sjia
versu
inact
quiescent
remit
sjia
logist
regress
model
use
find
panelbas
algorithm
minim
total
classif
error
discrimin
activ
system
sjia
inact
sjia
maximum
estim
probabl
wrongli
classifi
sampl
label
arrow
b
modifi
conting
tabl
show
percentag
classif
agre
clinic
diagnosi
c
discrimin
analysisderiv
predict
score
sampl
use
construct
receiv
oper
characterist
roc
curv
test
data
set
gener
bootstrap
sjia
system
flare
inact
sjia
data
use
deriv
estim
standard
error
confid
interv
roc
analysi
plot
roc
curv
vertic
averag
bootstrap
run
box
whisker
plot
show
vertic
spread
around
averag
distribut
standard
roc
auc
valu
fals
discov
panel
upon
classlabel
permut
data
set
cohort
sjia
f
qomrd
urin
peptidom
examin
fals
discov
biomark
panel
roc
auc
valu
number
fals
discov
sames
panel
roc
auc
valu
greater
origin
urin
biomark
panel
repres
red
vertic
line
divid
total
number
fals
discov
biomark
panel
led
estim
fals
discoveri
rate
fdr
unlik
outcom
chanc
multipl
hypothesi
test
direct
sequenc
catalog
natur
occur
normal
plasma
peptid
reveal
nest
fga
fgb
peptid
relat
sjia
urin
peptid
biomark
reason
least
sjia
urin
peptid
biomark
fga
peptid
biomark
like
filter
circul
urin
explor
fraction
normal
plasma
twodimension
chromatographi
extract
natur
occur
peptid
msm
peptid
sequenc
similar
plasma
peptid
direct
sequenc
effort
observ
fga
peptid
cluster
found
seven
fga
peptid
cluster
plasma
electron
supplementari
tabl
urin
peptid
biomark
fga
fga
fga
observ
plasma
fga
peptid
cluster
vii
detect
fga
although
peptid
found
publish
plasma
peptidom
sequenc
effort
urinari
peptid
fga
tabl
identif
peptid
found
normal
plasma
relat
sjia
urin
peptid
biomark
previous
publish
one
urinari
fga
peptid
found
activ
sjia
sampl
tabl
lack
one
two
ctermin
residu
compar
relat
plasma
peptid
thu
appear
deriv
exopeptidas
activ
urinari
peptid
differenti
express
activ
sjia
tabl
extend
beyond
c
terminu
close
relat
peptid
found
normal
plasma
suggest
may
gener
inhibit
normal
proteas
activ
sjia
urinari
fgb
peptid
found
sjia
similar
level
kd
comparison
group
less
system
inflamm
ident
peptid
found
normal
plasma
suggest
precursor
protein
increas
inflamm
data
indic
least
sjia
urin
peptid
biomark
like
origin
circul
filter
urin
identif
rant
pselectin
lselectin
sjia
plasma
flare
biomark
fibrinogen
degrad
fibrinogen
degrad
fragment
shown
biolog
import
molecul
numer
proinflammatori
action
reason
gener
sjia
urin
biomark
peptid
includ
deriv
fibrinogen
may
outcom
action
inflammatori
mediat
proteas
express
regul
gener
diseasespecif
degrad
pattern
sourc
protein
fibrinogen
explor
hypothesi
util
antibodi
array
consist
pair
captur
detect
antibodi
protein
chemokin
cytokin
protein
catabol
regul
cell
surfac
molecul
involv
leukocyt
adhes
profil
compar
f
q
plasma
sampl
demograph
shown
tabl
train
data
set
deriv
plasma
sampl
patient
time
sjia
system
flare
patient
time
quiescenc
classifi
discoveri
featur
select
nearest
shrunken
centroid
nsc
algorithm
perform
protein
ten
fold
intern
crossvalid
analysi
led
discoveri
candid
flare
signatur
consist
six
protein
rant
pselectin
lselectin
fig
use
nsc
algorithm
deriv
shrunken
class
mean
biomark
protein
abund
gaug
rel
quantiti
plasma
protein
saf
qom
sampl
assess
rel
resolv
power
biomark
fig
valid
antibodi
array
observ
concentr
sjia
plasma
also
determin
use
enzym
immunometr
assay
kit
raybiotech
inc
norcross
ga
data
shown
sjia
flare
biomark
protein
found
higher
level
plasma
sjia
flare
state
lda
classif
result
use
calcul
percentag
classif
agre
clinic
diagnosi
shown
modifi
conting
tabl
fig
left
panel
sixprotein
biomark
panel
classifi
sjia
flare
sampl
posit
agreement
nonflar
sampl
agreement
fig
left
panel
assess
perform
peptid
biomark
panel
classif
unknown
sampl
carri
experiment
bootstrap
approach
instead
silico
bootstrap
simul
sampl
belong
differ
visit
patient
even
sampl
assay
ie
bootstrap
experiment
test
bootstrap
test
total
sjia
sampl
demograph
shown
tabl
analyz
antibodi
array
sampl
patient
time
sjia
flare
sampl
eight
patient
time
sjia
quiescenc
figur
plot
linear
discrimin
probabl
peptid
biomark
panel
train
left
bootstrap
data
right
case
sampl
good
separ
highest
next
highest
probabl
classif
sixbiomark
panel
classifi
blindli
bootstrap
sampl
agreement
clinic
diagnosi
flare
sampl
agreement
quiescent
sampl
fig
right
panel
bootstrap
test
base
upon
discrimin
analysisderiv
predict
score
sampl
construct
roc
curv
evalu
perform
plasma
protein
panel
distinguish
flare
quiescenc
sampl
figur
summar
bootstrap
run
assay
sjia
flare
quiescent
sampl
deriv
estim
standard
error
confid
interv
roc
analysi
roc
analysi
yield
auc
valu
train
fig
identif
six
plasma
protein
sjia
plasma
flare
panel
six
plasma
biomark
protein
higher
abund
sjia
flare
rel
abund
nearest
shrunken
centroid
valu
util
repres
rel
abund
biomark
either
sjia
f
q
patient
class
b
logist
regress
model
use
find
panelbas
algorithm
minim
total
classif
error
discrimin
sjia
f
q
maximum
estim
probabl
wrongli
classifi
sampl
label
arrow
c
modifi
conting
tabl
show
percentag
classif
agre
clinic
diagnosi
discrimin
analysisderiv
predict
score
sampl
use
construct
receiv
oper
characterist
roc
curv
test
data
set
gener
silico
bootstrap
sjia
f
q
train
experiment
bootstrap
data
use
deriv
estim
standard
error
confid
interv
roc
analysi
plot
roc
curv
vertic
averag
bootstrap
run
box
whisker
plot
show
vertic
spread
around
averag
fig
left
panel
bootstrap
test
fig
right
panel
respect
urin
base
proteom
profil
novel
approach
may
lead
discoveri
noninvas
biomark
diagnos
patient
differ
diseas
aim
ultim
improv
clinic
outcom
given
new
emerg
analyt
technolog
data
mine
algorithm
urin
peptidom
becom
rich
resourc
discoveri
natur
occur
peptid
biomark
pediatr
diseas
urin
expect
becom
one
use
bodi
fluid
clinic
proteom
diagnosi
riskstratif
mass
spectrometrybas
urinari
protein
peptid
profil
led
discoveri
highli
inform
biomark
urogenit
nonurogenit
diseas
current
time
urin
proteom
appli
primarili
diseas
affect
kidney
urinari
tract
focu
chang
urin
reflect
system
inflamm
novel
potenti
broad
use
one
longterm
goal
use
urin
biomark
develop
clinic
test
noninvas
feasibl
frequent
sampl
determin
mind
urin
peptidom
sjia
patient
profil
identifi
natur
process
urin
peptid
biomark
peptid
emerg
candid
sjia
flare
panel
panel
found
robust
use
statist
analys
nonetheless
panel
requir
valid
use
new
sampl
set
suffici
size
guid
power
analysi
panel
discov
studi
appear
capabl
discrimin
patient
activ
sjia
quiescent
remit
diseas
similar
molecular
chang
plasma
protein
profil
urin
peptid
panel
may
detect
incipi
sjia
diseas
activ
prior
clinic
evid
diseas
order
offer
signific
clinic
advantag
justifi
routin
monitor
urin
biomark
test
would
sensit
histori
physic
exam
predict
impend
flare
would
need
predict
diseas
flare
selfresolv
therefor
requir
escal
medic
therapi
serial
evalu
urin
sampl
sjia
subject
use
mrm
analysi
perform
test
hypothesi
urin
peptid
panel
also
identifi
subject
activ
sjia
compar
kd
fi
abil
discrimin
sjia
patient
acut
system
inflammatori
condit
promis
futur
develop
diagnost
tool
howev
sjia
patient
studi
except
two
new
onset
patient
older
kd
fi
patient
collagen
bone
growth
connect
tissu
product
may
differ
substanti
therefor
develop
diagnost
marker
discrimin
new
onset
sjia
confound
acut
inflammatori
diseas
eg
kd
fi
requir
agematch
subject
continu
discoveri
effort
valid
current
biomark
panel
plan
assembl
larger
cohort
new
onset
sjia
anoth
potenti
util
sjia
urin
biomark
panel
distinguish
sjia
flare
infect
patient
known
sjia
scenario
requir
differ
therapeut
respons
urin
sampl
cohort
sjia
flare
sjia
patient
known
infect
assembl
valid
urin
peptid
biomark
panel
reveal
studi
parent
protein
urin
peptid
biomark
found
circul
kidney
exampl
fga
fgb
acutephas
plasma
protein
synthes
hepatocyt
megakaryocyt
found
high
level
circul
set
acut
chronic
inflamm
increas
fibrinogen
fibrin
deposit
within
joint
promin
indic
activ
sjia
flare
arthriti
hypothes
sjia
urin
peptid
biomark
may
result
chang
concentr
inflammatori
mediat
protein
catabol
regul
alter
level
peptid
ultim
filter
urin
gener
urinari
tract
local
proteas
activ
consequ
gener
diseasespecif
molecular
phenotyp
sjia
urin
support
model
other
found
urin
fga
peptid
biomark
plasma
would
suggest
fga
urin
peptid
biomark
like
present
circul
futur
prospect
studi
need
determin
whether
plasma
fga
fgb
peptid
diagnost
prognost
valu
sjia
diseas
manag
howev
umod
protein
deriv
blood
produc
thick
ascend
limb
loop
henl
kidney
plasma
analysi
fail
find
umod
peptid
suggest
umod
peptid
biomark
come
kidney
differenti
abund
umod
urin
peptid
biomark
sjia
suggest
sjia
like
impact
normal
kidney
function
renal
disord
sjia
patient
well
character
one
sjia
patient
character
aggress
diseas
cours
develop
renal
amyloidosi
year
diseas
onset
varieti
renal
disord
occur
patient
rheumatoid
arthriti
ra
may
due
underli
diseas
common
disord
associ
ra
membran
nephropathi
secondari
amyloidosi
focal
mesangi
prolif
glomerulonephr
rheumatoid
vascul
analges
nephropathi
unclear
whether
sjia
directli
affect
renal
function
indirectli
caus
renal
inflamm
would
interest
assess
chang
total
protein
peptid
excret
test
sjia
contrast
kdfi
sampl
amount
inflammatori
protein
excret
urin
chang
dramat
febril
state
often
associ
increas
protein
excret
futur
character
sjia
kdfi
urin
proteom
help
determin
whether
diseaserel
chang
total
protein
excret
explain
chang
urin
peptid
profil
observ
sjia
diseasespecif
alter
gene
transcript
affect
tissu
chang
balanc
proteolyt
antiproteolyt
activ
urin
propos
previous
may
also
contribut
alter
pattern
urin
peptid
sjia
explor
possibl
underli
mechan
relat
urin
peptid
gener
use
antibodi
array
protein
known
involv
inflamm
sjia
includ
certain
proteas
regul
plasma
profil
sjia
flare
quiescent
sampl
use
antibodi
array
identifi
biomark
panel
rant
pselectin
lselectin
present
higher
abund
sjia
flare
quiescenc
given
fibrinogen
substrat
possibl
regul
circul
may
directli
associ
gener
fga
peptid
biomark
ultim
enrich
urin
activ
sjia
shown
treatment
activ
rheumatoid
arthriti
golimumab
human
monoclon
antibodi
plu
methotrex
significantli
decreas
serum
eselectin
level
also
report
candid
key
cytokin
pathogenesi
sjia
notabl
synthesi
increas
sjia
kd
indic
differ
inflammatori
milieu
sometim
clinic
similar
diseas
differ
may
explain
differ
express
fga
peptid
biomark
urin
sjia
flare
kawasaki
diseas
observ
plselectin
part
plasma
biomark
panel
suggest
plselectinmedi
leukocyt
migrat
might
import
sjia
pathogenesi
possibl
mediat
recruit
andor
traffick
specif
leukocyt
subtyp
inflammatori
foci
previous
analysi
rheumatoid
arthriti
rh
specif
collagen
breakdown
product
indic
rhspecif
fragment
form
local
synovi
fluid
diseas
process
releas
circul
like
sjia
urin
peptid
biomark
similar
format
mechan
rhspecif
collagen
degrad
product
origin
due
local
inflamm
releas
circul
ultim
enrich
end
urin
togeth
urin
peptidom
target
plasma
profil
reveal
urin
biomark
panel
peptid
plasma
biomark
panel
six
plasma
protein
sjia
flare
signatur
shown
fig
integr
analys
suggest
differenti
abund
urin
peptid
sjia
urin
may
outcom
pathophysiolog
chang
initi
rant
plselectinmedi
inflammatori
respons
function
leukocytederiv
latter
would
influenc
protein
catabol
sjia
inflammatori
cytokin
may
also
directli
affect
level
express
substrat
protein
influenc
level
express
peptid
deriv
protein
evalu
urin
peptid
profil
futur
prospect
studi
test
robust
diagnosticprognost
valu
urin
peptid
biomark
may
provid
new
insight
sjia
pathogenesi
